"Drug Costs" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (FEES, PHARMACEUTICAL or PRESCRIPTION FEES).
| Descriptor ID |
D016527
|
| MeSH Number(s) |
N03.219.151.400.350 N05.300.375.300
|
| Concept/Terms |
Drug Costs- Drug Costs
- Cost, Drug
- Costs, Drug
- Drug Cost
|
Below are MeSH descriptors whose meaning is more general than "Drug Costs".
Below are MeSH descriptors whose meaning is more specific than "Drug Costs".
This graph shows the total number of publications written about "Drug Costs" by people in this website by year, and whether "Drug Costs" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 3 | 4 |
| 2009 | 2 | 2 | 4 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 2 | 2 | 4 |
| 2015 | 2 | 1 | 3 |
| 2016 | 2 | 1 | 3 |
| 2017 | 2 | 0 | 2 |
| 2019 | 1 | 1 | 2 |
| 2020 | 2 | 2 | 4 |
| 2021 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Costs" by people in Profiles.
-
Witte KK, Tsivgoulis G, Reynolds MR, Tsintzos SI, Eggington S, Ismyrloglou E, Lyon J, Huynh M, Egea M, de Brouwer B, Ziegler PD, Franco N, Joglekar R, Rosemas SC, Liu S, Thijs V. Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation. BMC Cardiovasc Disord. 2021 03 31; 21(1):160.
-
Nekui F, Galbraith AA, Briesacher BA, Zhang F, Soumerai SB, Ross-Degnan D, Gurwitz JH, Madden JM. Cost-related Medication Nonadherence and Its Risk Factors Among Medicare Beneficiaries. Med Care. 2021 01; 59(1):13-21.
-
Barry K, Slawson DC, Shaughnessy AF. Evidence to Avoid Overtesting and Overuse in Diabetes Mellitus and Other Diseases. Am Fam Physician. 2020 11 15; 102(10):583-584.
-
Soni A, Smith BS, Scornavacca T, McElnea B, Shakman A, Dickson E, McManus DD. Association of Use of an Integrated Specialty Pharmacy With Total Medical Expenditures Among Members of an Accountable Care Organization. JAMA Netw Open. 2020 10 01; 3(10):e2018772.
-
Greenwood BC. Introduction: Pharmacy Reimbursement. J Manag Care Spec Pharm. 2020 Jun; 26(6):702.
-
Goldsweig AM, Tak HJ, Chen LW, Aronow HD, Shah B, Kolte D, Desai NR, Szerlip M, Velagapudi P, Abbott JD. Relative Costs of Surgical and Transcatheter Aortic Valve Replacement and Medical Therapy. Circ Cardiovasc Interv. 2020 05; 13(5):e008681.
-
Baker JF, Leonard CE, Lo Re V, Weisman MH, George MD, Kay J. Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. Arthritis Rheumatol. 2020 07; 72(7):1067-1071.
-
Curtis JR, Xie F, Kay J, Kallich JD. Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis. Arthritis Res Ther. 2019 12 12; 21(1):285.
-
Galper BZ, Reynolds MR, Garg P, Secemsky EA, Valsdottir LR, Cohen DJ, Yeh RW. Cost-effectiveness analysis of short-duration dual antiplatelet therapy with newer drug-eluting stent platforms versus longer-duration dual antiplatelet therapy with a second-generation drug-eluting stent in elective percutaneous coronary intervention. Coron Artery Dis. 2019 05; 30(3):177-182.
-
Emmerick ICM, Campos MR, Luiza VL, Chaves LA, Bertoldi AD, Ross-Degnan D. Retrospective interrupted time series examining hypertension and diabetes medicines usage following changes in patient cost sharing in the 'Farm?cia Popular' programme in Brazil. BMJ Open. 2017 Nov 03; 7(11):e017308.